摘要
【目的】观察培美曲塞联合顺铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。【方法】34例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。培美曲塞联合顺铂治疗后评价疗效。[结果]34例患者均可评价，获得完全缓解CR3例，部分缓解PR12例，有效率为44．1％（15／34）。最主要的毒副反应为白细胞及血小板降低，但均可耐受。【结论】培美曲塞联合顺铂治疗老年中晚期NSCLC有较好疗效，可明显改善患者生存质量，毒副反应轻，易于耐受。
[Objective] To evaluate the clinical effect and toxicity of pemetrexed in treating advanced nonsmall cell lung eancer（NSCLC）. [Methods] Thirty four patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study. After treatment of pemetrexed plus cisplatin, the curative effect was evaluated. [Results]Complete remission （CR） was found in 3 cases and partial remission （PR） was found in 12 cases. The total response rate was 44.1% （15/34）. One-year survival rate was 47.1%（16/34）. The main side effects were leucopenia and thrombocytopenia, but they were tolerable. [Conclusion] The regimen of pemetrexed plus cisptation is effective, safe and well tolerable in the treatment of advanced NSCLC. It can significantly improve the quality of life of the patient.
出处
《医学临床研究》
CAS
2009年第11期2083-2085,共3页
Journal of Clinical Research
